Loading...

Teva Pharmaceutical Industries Limited

TEVANYSE
Healthcare
Drug Manufacturers - Specialty & Generic
$16.64
$-0.36(-2.09%)

Teva Pharmaceutical Industries Limited TEVA Peers

See (TEVA) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
TEVA$16.65-2.09%19B-14.42-$1.15N/A
ZTS$155.68-0.99%69.4B28.02$5.56+1.20%
TAK$15.09+0.77%47.4B65.52$0.23+3.91%
HLN$10.35-1.43%46.9B24.24$0.43+1.12%
ITCI$131.87+0.00%14B-180.64-$0.73N/A
RDY$15.05-2.94%12.8B19.65$0.78+0.62%
NBIX$125.59-1.71%12.5B42.96$2.95N/A
CTLT$63.48+0.00%11.5B-27.84-$2.28N/A
VTRS$8.93+0.39%10.7B-2.87-$3.18+5.29%
RGC$15.99-26.42%10B-2019.00-$0.01N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

TEVA vs ZTS Comparison

TEVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TEVA stands at 19B. In comparison, ZTS has a market cap of 69.4B. Regarding current trading prices, TEVA is priced at $16.65, while ZTS trades at $155.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TEVA currently has a P/E ratio of -14.42, whereas ZTS's P/E ratio is 28.02. In terms of profitability, TEVA's ROE is -0.21%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, TEVA is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for TEVA.

Stock Price Comparison

Loading...

Frequently Asked Questions

;